These drugs include advanced sGC stimulators such as Vericiguat (BAY 1021189) and Riociguat (BAY 63–2521), the latter having received FDA approval for pulmonary hypertension and heart failure50,51, as well as novel short-acting sGC activators that lack hypotensive side effects, such as TY-55002, a candidate for the treatment of patients with acute decompensated heart failure52. Here, SGCB is linked to pulmonary arterial hypertension.